Sangamo Announces Capsid License Agreement with Lilly to Delivery Genomic Medicines for Diseases of the Central Nervous System

Translating groundbreaking science into tomorrow’s cures

Explore our science

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Explore our latest corporate presentation by clicking below to stay informed and gain valuable insights into our company’s vision, achievements, and roadmap.

View the corporate presentation

The Latest at Sangamo


News

Company pipeline and business development opportunities

Clinical Trials

NEUROLOGY PIPELINE - WHOLLY OWNED
Indication Preclinical Phase 1/2 Pivotal Partner
Idiopathic Small Fiber Neuropathy (ST-503)
None
Prion Disease
None
Undisclosed neurology target(s)
None
NEUROLOGY PIPELINE - PARTNERED
Indication Preclinical Phase 1/2 Pivotal Partner
Genentech
Genentech logo
Undisclosed neurology target
Cargo Icon Capsid Icon
Genentech
Genentech logo
Undisclosed neurology target
Capsid Icon
Astellas
Astellas logo
Undisclosed neurology target
Capsid Icon
Lilly
Lilly logo
Alexion
alexion logo
Takeda
takeda logo
OTHER PROGRAMS
Indication Preclinical Phase 1/2 Pivotal Partner
Hemophilia A (Giroctogene fitelparvovec)
Pfizer
pfizer logo

*until April 21, 2025

Fabry Disease (Isaralgagene civaparvovec)
None
Cargo Icon Cargo
Capsid Icon Capsid